Genedrive Regulatory News (GDR)

Company Epistem Plc

TIDM EHP.L (AIM)

Headline Pre-Close Trading Update

Released 4th August 2011

Number

Epistem Holdings Plc

("Epistem" or "the Company")

Pre-Close Trading Update and Board Change

Epistem (AIM: EHP), the biotechnology and personalised medicine company, today announces a pre-close trading statement for the year ended 30th June 2011.

Following a positive year during which all the Company's business units made good progress, the Company is pleased to announce that trading over the full year is expected to be profitable and broadly in-line with market forecasts.

The Company expects to release its final results for the year ended 30th June 2011 on Tuesday 11th October 2011 and will hold an analysts' meeting on the day at Peel Hunt LLP, 111 Old Broad Street, London EC2N 1PH.

The Company also announces that, with immediate effect, Dr. Gerard Brady will be stepping down from the Epistem Board. The Company will continue to benefit from Ged's experience as he will join the Scientific Advisory Board in his new role as scientific adviser to the Company.

For further information contact:

Epistem Plc

Matthew Walls, Chief Executive Officer ++44 161 606 7258

John Rylands, Chief Financial Officer

Peel Hunt LLP

Nominated Adviser: James Steel/Vijay Barathan ++44 207 418 8900 

De Facto Financial

Mike Wort/Anna Dunphy ++44 207 556 1063

Notes for editors

Epistem is a biotechnology and personalised medicine company commercialising its expertise in epithelial stem cells in the areas of oncology, gastrointestinal and dermatological diseases. Epistem develops innovative therapeutics, biomarkers and diagnostics alongside providing contract research services to drug development companies. The Group's core expertise is focused on the regulation of adult stem cells located in epithelial tissue, which includes the gastrointestinal tract, skin, hair follicles, breast and prostate.